NeuroMetrix, Inc.

NasdaqCM:NURO Stock Report

Market Cap: US$9.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

NeuroMetrix Management

Management criteria checks 4/4

NeuroMetrix's CEO is Shai Gozani, appointed in Jun 1996, has a tenure of 28.92 years. total yearly compensation is $475.85K, comprised of 93.3% salary and 6.7% bonuses, including company stock and options. directly owns 0.75% of the company’s shares, worth $67.43K. The average tenure of the management team and the board of directors is 11.8 years and 14.4 years respectively.

Key information

Shai Gozani

Chief executive officer

US$475.9k

Total compensation

CEO salary percentage93.32%
CEO tenure28.9yrs
CEO ownership0.8%
Management average tenure11.8yrs
Board average tenure14.4yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 20

NeuroMetrix reports Q3 results

NeuroMetrix press release (NASDAQ:NURO): Q3 net loss of $1.6M Revenue of $2M (-4.8% Y/Y).
Seeking Alpha • Sep 23

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Summary DPNCheck is a screening product sold to MA insurers which gives better member health outcomes, lower cost, and increased revenue for MA insurers. The product has consistently grown >20%. Discontinuation of Quell marketing in 2018 is masking the strong, underlying growth in DPNCheck. The result is rev growth is now accelerating. Clean cap structure and balance sheet with $3.24/share which is sufficient to fund the business to profitability. Potential $15/share fair value in 5 years based on 20x FCF. For those who follow small cap med devices, NURO's business is ~85% SMLR and ~15% ZYXI. Thesis Overview The most profitable investments in microcap stocks are made when businesses reach inflection points, then go on to deliver years of organic growth and inflect to profitability. I believe that NeuroMetrix (NURO) is at that turning point. After a long history of losses and shareholder dilution from spending on R&D that didn’t work and attempts to sell medical devices that were not successful, NURO now has a clean capital structure and balance sheet with a proven business that is scaling with strong unit economics. NURO has a promising medical device called DPNCheck, which is used for early disease detection of diabetic polyneuropathy (DPN) and is sold to Medicare Advantage ((MA)) insurers with >80% of revenue from consumables. They are following the same business model as Semler Scientific (SMLR), who built a strong business by showing MA insurers that early disease detection leads to better patient outcomes, lower cost to serve patients, and increased revenue for the MA insurers through appropriately risk-coding patients. DPNCheck launched in 2011 and has grown at a >20% CAGR in recent years to $7.4m revenue in 2022. That >20% organic growth is set to continue indefinitely at ~80% gross margins. Most importantly, DPNCheck’s go-to-market is very efficient because they sell at the top level to UNH and HUM, who then push down to their organization. DPNCheck’s consistent growth and strong unit economics has been masked by NURO’s Quell product which the company sells direct-to-consumer as an over-the-counter (OTC) medical device for pain management. The company created a slick product that works well and grew it to ~$14m of revenue in 2017, but had to spend aggressively on online advertising and TV ads to get that growth (negative unit economics). In 2018, management realized their market efforts were not going to pay off for Quell because the market for TENS-like devices is too crowded, so they stopped advertising. That led to revenue declining to <$2m in 2022, which is now mostly consumable pads that are ordered by customers and paid through credit card (no insurance pay). Management pivoted the strategy for their Quell device to focusing on gaining breakthrough designation by the FDA for patients with Fibromyalgia. 10 million Americans suffer from debilitating pain from Fibromyalgia. Quell may receive FDA clearance for the device for patients with Fibromyalgia in late 2022 and begin marketing to physicians in early 2023. Having a physician prescription means they can pursue insurance reimbursement which results in a much, much higher revenue per device than selling in the highly competitive over-the-counter market. Zynex sells a prescription pain management device, but sells primarily through physical therapists and does not have specific indications or data supporting efficacy, like Quell does. The takeaways are that NURO’s revenue growth is accelerating. After revenue declines in 2018-2020 from unprofitable Quell OTC revenue falling, NURO grew 12% in 2021 and will grow 12% in 2022. I expect revenue growth to accelerate to >20% and maintain that growth for several years, primarily from DPNCheck. After significant losses from Quell advertising, NURO raised highly dilutive preferred capital in the 2016-2018 range (please refer to NURO's form 10-K filings for details). After cleaning up the cap structure, NURO raised over $20m through DRIP equity raises (selling shares directly into the market) in 2020 and 2021 (including some very attractive sales prices last year when the stock price spiked >$10/share). All this leads to an ugly and messy past, in which the share count has gone way up and the stock price way down. However, I believe that evaluating the business based on current facts, shows that NURO is an undervalued med device company that is well capitalized to pursue this growth. The company now has a clean capital structure with 7.1m shares and 0.5m options for management, no debt, no preferred, no warrants, and $23m of cash. I expect NURO to burn $3.8m in 2022, $2.7m in 2023, $1.7m in 2024, and $0.2m in 2025. Then it should start generating cash, with +$2.1m in 2026, +$4.9m in 2027. I model trough cash of $16m in 2025. On profitability, I expect the business will generate $5m of free cash flow in 2027 and be worth 20x FCF plus net cash, which gives a value of $15/share. Studying Semler’s history, once the business crossed $14m in revenue, it inflected to profitability and never looked back. DPNCheck currently has $7.4m in revenue, and I expect it to cross that threshold exiting 2025. SMLR has proven how strong the unit economics are in this business with 37% EBITDA margins in 2Q22. Revenue Mix Shift Well Underway Higher quality, more profitable DPNCheck revenue is replacing negative margin Quell revenue (when including expensive marketing spend in the past). As rev mix continues to shift, the growth will accelerate and the business will reach profitability.
Seeking Alpha • Jul 21

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

NeuroMetrix press release (NASDAQ:NURO): Q2 GAAP EPS of -$0.17. Revenue of $2.1M (-5.0% Y/Y).
Analysis Article • May 11

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 19

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Sep 09

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

NeuroMetrix is a medical devices company with three commercialized products. The Company says it was spun off from the Harvard-MIT Division of Health Sciences and Technology in 1996. The Company has active R&D programs to expand into new indications and improve existing technologies.
Analysis Article • Jul 21

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, NeuroMetrix...
Analysis Article • Jan 27

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

CEO Compensation Analysis

How has Shai Gozani's remuneration changed compared to NeuroMetrix's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

-US$8m

Sep 30 2024n/an/a

-US$8m

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$476kUS$444k

-US$7m

Sep 30 2023n/an/a

-US$6m

Jun 30 2023n/an/a

-US$5m

Mar 31 2023n/an/a

-US$5m

Dec 31 2022US$645kUS$415k

-US$4m

Sep 30 2022n/an/a

-US$5m

Jun 30 2022n/an/a

-US$4m

Mar 31 2022n/an/a

-US$3m

Dec 31 2021US$558kUS$415k

-US$2m

Sep 30 2021n/an/a

-US$2m

Jun 30 2021n/an/a

-US$1m

Mar 31 2021n/an/a

-US$1m

Dec 31 2020US$181kUS$181k

-US$2m

Sep 30 2020n/an/a

-US$3m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$775kUS$422k

-US$4m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

-US$3m

Mar 31 2019n/an/a

US$908k

Dec 31 2018US$478kUS$415k

US$24k

Compensation vs Market: Shai's total compensation ($USD475.85K) is about average for companies of similar size in the US market ($USD661.71K).

Compensation vs Earnings: Shai's compensation has been consistent with company performance over the past year.

CEO

Shai Gozani (59 yo)

28.9yrs
Tenure
US$475,850
Compensation

Dr. Shai N. Gozani, M.D., Ph D., founded Neurometrix Inc. in 1996 and has been President since 2002 and Chief Executive Officer since 1997 and Secretary July 2008. He has been the Chairman of the Board at...

Leadership Team

NamePositionTenureCompensationOwnership
Shai Gozani
Founder28.9yrsUS$475.85k0.75%
$ 67.4k
Thomas Higgins
Senior VP15.7yrsUS$371.60k0.57%
$ 51.6k
Xuan Kong
Chief Data Scientist7.9yrsno datano data
Susan Bell
Senior Vice President of Population Health & Value Based Care3.6yrsno datano data
11.8yrs
Average Tenure

Experienced Management: NURO's management team is seasoned and experienced (11.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Shai Gozani
Founder28.9yrsUS$475.85k0.75%
$ 67.4k
Nancy Katz
Independent Director14.4yrsUS$105.00k0.37%
$ 33.1k
David Goodman
Independent Director20.9yrsUS$110.00k0.37%
$ 33.1k
Joshua Horowitz
Independent Director1.1yrsno data1.23%
$ 110.4k
David Van Avermaete
Independent Director11.7yrsUS$105.00k0.37%
$ 33.1k
14.4yrs
Average Tenure
64yo
Average Age

Experienced Board: NURO's board of directors are seasoned and experienced ( 14.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/01 16:26
End of Day Share Price 2025/05/01 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NeuroMetrix, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinH.C. Wainwright & Co.
Anthony VendettiMaxim Group